CN110437205B - 吡啶烯基哌啶衍生物及其用途 - Google Patents

吡啶烯基哌啶衍生物及其用途 Download PDF

Info

Publication number
CN110437205B
CN110437205B CN201910778613.0A CN201910778613A CN110437205B CN 110437205 B CN110437205 B CN 110437205B CN 201910778613 A CN201910778613 A CN 201910778613A CN 110437205 B CN110437205 B CN 110437205B
Authority
CN
China
Prior art keywords
compound
formula
alkyl
methyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910778613.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110437205A (zh
Inventor
金传飞
钟文和
薛亚萍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong HEC Pharmaceutical Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of CN110437205A publication Critical patent/CN110437205A/zh
Application granted granted Critical
Publication of CN110437205B publication Critical patent/CN110437205B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN201910778613.0A 2018-08-24 2019-08-22 吡啶烯基哌啶衍生物及其用途 Active CN110437205B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018109698375 2018-08-24
CN201810969837 2018-08-24

Publications (2)

Publication Number Publication Date
CN110437205A CN110437205A (zh) 2019-11-12
CN110437205B true CN110437205B (zh) 2022-07-08

Family

ID=68437065

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910778613.0A Active CN110437205B (zh) 2018-08-24 2019-08-22 吡啶烯基哌啶衍生物及其用途

Country Status (7)

Country Link
US (1) US11858910B2 (https=)
EP (1) EP3841096A4 (https=)
JP (1) JP7405834B2 (https=)
CN (1) CN110437205B (https=)
AU (1) AU2019323450B2 (https=)
CA (1) CA3107145A1 (https=)
WO (1) WO2020038435A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111187252B (zh) * 2019-11-22 2023-06-09 广东东阳光药业有限公司 吡啶酰基氮杂螺庚烷衍生物及其用途
CN111187251B (zh) * 2019-11-22 2023-06-09 广东东阳光药业有限公司 吡啶酰基哌啶衍生物及其用途
CN111943930B (zh) * 2020-08-25 2022-11-01 南京三元阳普医药科技有限公司 Lasmiditan的合成工艺
CN114685443B (zh) * 2020-12-29 2023-07-18 广东东阳光药业有限公司 吡啶烯基哌啶衍生物的盐及其用途
CN114685440B (zh) * 2020-12-29 2023-07-18 广东东阳光药业有限公司 吡啶烯基哌啶衍生物的盐及其用途
US20240083870A1 (en) * 2020-12-29 2024-03-14 Sunshine Lake Pharma Co., Ltd. Salts of pyridinylmethylenepiperidine derivatives and uses thereof
CN114685441B (zh) * 2020-12-29 2023-07-18 广东东阳光药业有限公司 吡啶烯基哌啶衍生物的盐及其用途
CN114685444B (zh) * 2020-12-29 2023-07-18 广东东阳光药业有限公司 吡啶烯基哌啶衍生物的盐及其用途
CN112939952A (zh) * 2021-02-02 2021-06-11 深圳市第二人民医院(深圳市转化医学研究院) 一种3-羟基查尔酮衍生物及其用途
CN112898276A (zh) * 2021-02-02 2021-06-04 深圳市第二人民医院(深圳市转化医学研究院) 一种查尔酮衍生物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1777584A (zh) * 2003-04-18 2006-05-24 伊莱利利公司 作为5－ht1f激动剂的(哌啶氧基)苯基、(哌啶氧基)吡啶基、(哌啶硫基)苯基和(哌啶硫基)吡啶基化合物
CN1849307A (zh) * 2003-09-12 2006-10-18 伊莱利利公司 作为5－ht1f激动剂的取代的2－羰基氨基－6－哌啶氨基吡啶和取代的1－羰基氨基－3－哌啶氨基苯
CN100352817C (zh) * 2002-03-29 2007-12-05 伊莱利利公司 用作5－HT1f激动剂的吡啶酰基哌啶
CN101595102A (zh) * 2006-10-18 2009-12-02 辉瑞产品公司 二芳基醚脲化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
US6133290A (en) 1998-07-31 2000-10-17 Eli Lilly And Company 5-HT1F agonists
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
DE602004008338T2 (de) 2003-12-17 2008-05-29 Eli Lilly And Co., Indianapolis Substituierte (4-aminocyclohexen-1-yl) phenyl and (4-aminocyclohexen-1-yl) pyridinyl verbindungen als 5-ht1f agonisten
CN101602708B (zh) * 2008-06-10 2012-11-21 江苏国华投资有限公司 芳烷醇哌啶衍生物及其在制备抗抑郁症药物中的应用
TW201028421A (en) 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers
GB201114448D0 (en) 2011-08-22 2011-10-05 Takeda Pharmaceutical Compounds and their use
MX2016016488A (es) 2014-08-27 2017-03-30 Hoffmann La Roche Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar).
GB201416513D0 (en) * 2014-09-18 2014-11-05 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100352817C (zh) * 2002-03-29 2007-12-05 伊莱利利公司 用作5－HT1f激动剂的吡啶酰基哌啶
CN1777584A (zh) * 2003-04-18 2006-05-24 伊莱利利公司 作为5－ht1f激动剂的(哌啶氧基)苯基、(哌啶氧基)吡啶基、(哌啶硫基)苯基和(哌啶硫基)吡啶基化合物
CN1849307A (zh) * 2003-09-12 2006-10-18 伊莱利利公司 作为5－ht1f激动剂的取代的2－羰基氨基－6－哌啶氨基吡啶和取代的1－羰基氨基－3－哌啶氨基苯
CN101595102A (zh) * 2006-10-18 2009-12-02 辉瑞产品公司 二芳基醚脲化合物

Also Published As

Publication number Publication date
JP7405834B2 (ja) 2023-12-26
EP3841096A4 (en) 2022-05-18
CA3107145A1 (en) 2020-02-27
EP3841096A1 (en) 2021-06-30
WO2020038435A1 (en) 2020-02-27
US20210188803A1 (en) 2021-06-24
AU2019323450A1 (en) 2021-02-11
AU2019323450B2 (en) 2025-04-10
CN110437205A (zh) 2019-11-12
JP2021536433A (ja) 2021-12-27
US11858910B2 (en) 2024-01-02

Similar Documents

Publication Publication Date Title
CN110437205B (zh) 吡啶烯基哌啶衍生物及其用途
CN111333648B (zh) 8-取代的芳香环乙烯基黄嘌呤衍生物及其用途
CN111004214B (zh) 吡啶酰基哌啶衍生物及其用途
CN110272425B (zh) 吡啶酰基八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN112300165B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN110981876B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN107759620B (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其使用方法和用途
CN109988170B (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN111187252B (zh) 吡啶酰基氮杂螺庚烷衍生物及其用途
CN111187251B (zh) 吡啶酰基哌啶衍生物及其用途
CN110845402B (zh) 吡啶亚甲基哌嗪衍生物及其用途
CN109988169B (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN114728929A (zh) 吡啶亚甲基哌啶衍生物及其用途
CN111018856B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN111072676B (zh) 含氮稠合三环衍生物及其用途
CN111072675A (zh) 含氮稠合三环衍生物及其用途
CN110922408B (zh) 3H-[1,2,3]三唑并[4,5-d]嘧啶-5-胺衍生物及其用途
CN110963999B (zh) 2,3-二氢苯并呋喃酰胺衍生物及其用途
CN111072663B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN110938064B (zh) N-取代哌啶酰胺衍生物及其用途
CN111072604A (zh) α-氨基酰胺衍生物及其用途
CN109776373B (zh) 酰胺取代的吡咯烷酰胺衍生物及其用途
CN109761892B (zh) 含氮杂环基团取代的酰胺衍生物及其用途
CN109956945B (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN118063445A (zh) 吡咯烷酰胺衍生物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd.

Address before: 523808 No. 1 Industrial North Road, Songshan Industrial Park, Songshan, Guangdong, Dongguan, Hubei

Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd.

CP03 Change of name, title or address